Alerta

PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM

Resumen de: AU2024234831A1

In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.

MDA5 INHIBITION AS A BROAD DEFENSE AND HEALTHSPAN EXTENDING STRATEGY

Resumen de: WO2025202219A1

The present invention relates to the use of Melanoma Differentiation-Associated protein (MDA5) inhibitors for enhancing the number of p16high immune cells in vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is moreover herein reported that p16high immune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. Mechanistically, it is shown that inhibition of MDA5 induces an increase in p16high immune cells subsets that, in turn, establishes a low adenosine environment and disease tolerance. The present invention also relates to a pharmaceutical composition comprising immune cells such as CAR-T cells in which the MDA5 expression and/or activity is inhibited, and its use for various therapeutic purposes.

PHARMACEUTICAL COMPOSITION FOR TREATING OR RELIEVING COVID-19 AND FORMULATION COMPRISING SAME

Resumen de: EP4623909A1

The present invention relates to a pharmaceutical composition comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is compound 1, an ester corresponding thereto, a salt corresponding thereto, a salt of the ester corresponding thereto, or a combination of the substances, and the second active ingredient is ATV014, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof. The molar ratio of the first active ingredient to the second active ingredient is 50: 1-1:50. The composition has relatively good prospects for pharmaceutical development.

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

Resumen de: MX2025009166A

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

PLANT-BASED COMPOSITIONS AND METHODS FOR MODULATION OF INFLAMMATORY RESPONSE POST VIRAL INFECTION

Resumen de: MX2025009564A

A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt% total catechins, at least 20 wt% total chlorogenic acids, and optionally up to 30 wt% total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.

USE OF SHENLING BAIZHU IN PREPARING MEDICAMENT FOR TREATING POST-HEALING SEQUELAE OF NOVEL CORONAVIRUS INFECTED PERSON

Nº publicación: EP4623924A1 01/10/2025

Solicitante:

BEIJING HANDIAN PHARMACEUTICAL CO LTD [CN]
Beijing Handian Pharmaceutical Co., Ltd

Resumen de: EP4623924A1

Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of shortness of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.